Retifanlimab: First Approval

Retifanlimab: First Approval

Retifanlimab (retifanlimab-dlwr; ZYNYZ TM ) is a programmed cell death 1 receptor-blocking antibody that is being developed by Incyte Corporation for the treatment of solid tumours, both as monotherapy and in combination with other agents. Retifanlimab recently received accelerated approval for the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Drugs (New York, N.Y.) N.Y.), 2023-06, Vol.83 (8), p.731-737
1. Verfasser: Kang, Connie
Format: Artikel
Sprache:eng
Schlagworte:
AdisInsight Report
Adult
Antibodies
Antibodies, Monoclonal - pharmacology
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Humanized - pharmacology
Antibodies, Monoclonal, Humanized - therapeutic use
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Apoptosis
Autoimmune diseases
Blocking antibodies
Cancer therapies
Carcinoma, Merkel Cell - drug therapy
Cell death
Collaboration
Drug Approval
Endometrial cancer
HIV
Human immunodeficiency virus
Humans
Immune Checkpoint Inhibitors - therapeutic use
Internal Medicine
Licensed products
Ligands
Lymphocytes
Medicine
Medicine & Public Health
Metastases
Metastasis
Patients
Pharmacodynamics
Pharmacokinetics
Pharmacology/Toxicology
Pharmacotherapy
Radiation therapy
Skin Neoplasms - drug therapy
Solid tumors
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Retifanlimab (retifanlimab-dlwr; ZYNYZ TM ) is a programmed cell death 1 receptor-blocking antibody that is being developed by Incyte Corporation for the treatment of solid tumours, both as monotherapy and in combination with other agents. Retifanlimab recently received accelerated approval for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma. This article summarizes the milestones in the development of retifanlimab leading to this first approval for Merkel cell carcinoma.
ISSN:0012-6667
1179-1950
DOI:10.1007/s40265-023-01884-7